Strides Pharma Science Ltd
NSE:STAR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its 3-Year Average (15.6), the stock would be worth ₹1 181.45 (18% upside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 13.2 | ₹1 000.25 |
0%
|
| 3-Year Average | 15.6 | ₹1 181.45 |
+18%
|
| 5-Year Average | 15.6 | ₹1 181.45 |
+18%
|
| Industry Average | 25.6 | ₹1 930.07 |
+93%
|
| Country Average | 23.3 | ₹1 757.26 |
+76%
|
Forward EV/EBIT
Today’s price vs future ebit
| Today's Enterprise Value | EBIT | Forward EV/EBIT | ||
|---|---|---|---|---|
|
₹80.9B
|
/ |
Jan 2026
₹7.1B
|
= |
|
|
₹80.9B
|
/ |
Mar 2026
₹9.5B
|
= |
|
|
₹80.9B
|
/ |
Mar 2027
₹10.9B
|
= |
|
Forward EV/EBIT shows whether today’s EV/EBIT still looks high or low once future ebit are taken into account.
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| IN |
|
Strides Pharma Science Ltd
NSE:STAR
|
92.2B INR | 13.2 | 18 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
875.9B USD | 30.4 | 42.1 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
555.5B USD | 21.7 | 26.4 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 13.2 | 19.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
231.9B GBP | 23.4 | 30 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
294.7B USD | 12 | 15.9 | |
| CH |
|
Novartis AG
SIX:NOVN
|
228B CHF | 16.1 | 20.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 970 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 9.6 | 11.2 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
156.7B USD | 10.3 | 20.1 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
119B USD | 8.8 | 16.9 |
Market Distribution
| Min | 0.4 |
| 30th Percentile | 15.7 |
| Median | 23.3 |
| 70th Percentile | 34.7 |
| Max | 48 145.1 |
Other Multiples
Strides Pharma Science Ltd
Glance View
Strides Pharma Science Ltd. engages in the development, manufacture and distribution of Internet Protocol-led generics and bio-pharmaceutical products. The company is headquartered in Bangalore, Karnataka. The company went IPO on 2000-02-03. The firm is focused on development and manufacture of IP-led niche and pharmaceutical products. The company operates through two segments: Pharmaceutical and Bio-pharmaceutical. Its geographical segment includes Africa, Australia, Asia (excluding India), North America, Europe, India, and Others. The firm manufactures a range of niche and pharmaceutical products, including a range of dosage forms such as, liquids, creams and ointments, soft gels, sachets, tablets, and modified release dosage formats. The company has eight manufacturing units located in India (Bengaluru-two sites, Puducherry, and Chennai), Singapore, Italy (Milan), the United States (Florida) and Kenya (Nairobi). The company is also engaged in manufacturing soft gelatin capsules. The company develops and manufactures drugs in the anti-retroviral, anti-malarial, anti-tuberculosis, hepatitis, and other infectious disease drug segments for its institutional business.
